Functional human myeloid cells in BRGSF-HIS humanized mice enable myeloid-directed therapy assessment
BRGSF-HIS for myeloid-directed therapy assessment
Translational preclinical assessment of myeloid-targeting therapies is considered challenging due to the reduced availability of humanized mouse models expressing both lymphoid and myeloid compartments. Most of the humanized models harboring myeloid compartments overexpress human cytokines, leading to body weight loss, anemia, and a short life span. A recent report described the BRGSF-HIS as an alternative model displaying all major human hematopoietic cell subsets, such as B, T, natural killer (NK), dendritic cells (DCs), plasmacytoid cells (pDCs) and monocytes/macrophages. Human myeloid cells developed in the BRGSF-HIS mice without side effects and human immune system engraftment is stable for over a year (Labarthe et al., 2019), favoring long terms studies with agents requiring a wide therapeutic window.
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our modelsScientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in FranceCustomer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfactionCollaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate